PubMed Health⌕ Search

Biomedical subjects

R Rasch

Publications and source records attributed to R Rasch.

52 records · Page 3Linked to original sources
PubMed1981

Experimental diabetic cardiopathy preventable by insulin treatment.

A quantitative histologic study of hearts from streptozotocin-diabetic and nondiabetic rats was performed. The diabetic rats comprised as group of poorly controlled and one of well-controlled insulin-treated animals. The relative amount of connective tissue was statistically significantly increased in the poorly controlled diabetic rats (p less than 0.01). In the well-controlled group of diabetic rats, the relative amount of connective tissue was the same as in the controls. The number of cells in tunica media of the larger intramural coronary arteries was statistically significantly increased in the diabetic rats in a poorly controlled state (p less than 0.01). There was no difference between the control group and the diabetic rats in a well-controlled metabolic state. Thrombosis or calcification in tunica media of the large intramural coronary arteries was not observed. The present study is reconcilable with the hypothesis of a diabetic cardiopathy and strongly emphasizes the importance of careful insulin treatment.

Animals↗
PubMed1980

Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Albumin excretion.

A single antibody radioimmunoassay has been used to measure albumin excretion in 3 groups of female Wistar rats. Two groups had streptozotocin diabetes and were treated daily with insulin for 6 months. In one of the diabetic groups good glycaemic control was attempted and throughout the 6 months plasma glucose levels were fairly close to normal (92 +/- 33 mg/100 ml at 2300 h and 186 +/- 9 mg/100 ml at 0800 h). In the other diabetic group poor control was intended and the group had consistent high plasma glucose levels (576 +/- 89 mg/100ml and 460 +/- 43 mg/100 ml). The third group was a non-diabetic control group. -- Albumin excretion was measured on two occasions: before the induction of diabetes and after 6 months of diabetes. The geometric mean albumin excretion increased from 0.38 to 2.56 mg/24 h in the 18 non-diabetic controls. In the 20 diabetic rats in "good" control the geometric mean albumin excretion increased from 0.37 to 1.58 mg/24 h (NS compared with controls) and in the group of 22 rats in poor control albumin excretion increased from 0.35 to 6.54 mg/24 h. -- The increase in albumin excretion in rats in poor control differed significantly both from that of the non-diabetic controls (2p = 0.023) and from that of the "well-controlled" diabetic rats (2p = 0.00011).

Albuminuria↗
PubMed1979

Control of blood glucose levels in the streptozotocin diabetic rat using a long-acting heat-treated insulin.

Diurnal plasma glucose levels have been studied two hourly in streptozotocin diabetic rats during insulin treatment. Protamine Zinc Insulin induced a very steep fall in plasma glucose level from 359 +/- 100 (SD) mg/100 ml to 91 +/- 49 mg/100 ml within two hours. Plasma glucose was then low (13-60 mg/100 ml) until after 18 hours when an equally steep rise in glucose concentration ocurred. Six other insulin preparations and several insulin treatment regimens were tested with the aim of normalising the 24 hour plasma glucose profile of streptozotocin diabetic rats. One preparation, a non-commercial, very long acting Ultralente NOVO (Mc, ox pH 5.5) yielded a diurnal plasma glucose profile reasonably close to normal when it was administered once a day and when the dose was based on daily blood glucose measurements. Mean plasma glucose was 122 +/- 55 mg/100 ml with a nadir of 55 +/- 15 and a maximal of 187 +/- 99 mg/100 ml.

Animals↗
PubMed1979

Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment.

Glomerular basement membrane thickness (GBMT) has been measured in streptozotocin diabetic rats treated with insulin. The study included 3 groups of 8 rats each: 1) a 'well-controlled' group of diabetic rats under insulin treatment with a plasma glucose level reasonable close to normal values, 2) a 'poorly-controlled' group also under insulin treatment with constant high plasma glucose values, and 3) an age and weight matched non-diabetic control group. After 6 months of diabetes, GBMT was measured applying an intercept method on 3 glomerular cross sections from each of the 24 animals. The measurements showed that mean GBMT was 132.2. nm in the non-diabetic control rats and 131.6 nm in the 'well-controlled' diabetic rats. In the 'poorly-controlled' group the man GBMT was 140.4 nm, i.e. statistically significant increased when compared to each of the two other groups, 2p = 0.022 and 0.012 respectively. The results demonstrate that good blood glucose control in rats preserves normal GBMT.

Animals↗
PubMed1979

Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Kidney size and glomerular volume.

Kidney weight and glomerular volume have been studied in groups of insulin-treated streptozotocin diabetic rats maintained at high, or nearly normal plasma glucose levels. Kidney weight and glomerular volume in these groups were compared to a non-diabetic control group. --Rats with nearly normal plasma glucose levels (95 +/- 35 to 182 +/- 20 mg/100 ml) had the same kidney weight as the non-diabetic controls, 1.04 +/- 0.14 and 1.07 +/- 0.09 g, respectively. In the rats with constant high plasma glucose (338 +/- 71 to 555 +/- 86 mg/100 ml) kidney weight was significantly increased, 1.73 +/- 0.20 g, compared to each of the two other groups. Glomerular volume was 0.559 millimicron3 in the diabetic animals with nearly normal plasma glucose, a value very close to that of the non-diabetic controls, 0.587 milimicron3. In animals with high plasma glucose concentrations glomerular volume was 0.775 millimicron3, 2 p less than 0.03 compared with both other groups. --The study indicates that good diabetic control for 6 months prevents the development of large kidneys and large glomeruli in dibatic rats.

Animals↗
PubMedDate not supplied

No influence of an aldose reductase inhibitor on glycogen deposition in tubules from streptozotocin diabetic rats.

Streptozotocin diabetic rats were divided into two groups. One diabetic group was given an aldose reductase inhibitor (Statil) throughout the study and the other group was left untreated. An additional group of nondiabetic rats was included in the study. After 7 months, the kidneys were perfusion fixed and blocks of tissue were sampled systematically and uniformly throughout the kidney cortex. Plastic embedded blocks were sectioned and used to determine the volume fraction of tubular glycogen by light microscopy. No difference was found between the two diabetic groups in glycogen deposits in the cortical thick ascending limb of Henle's loop, expressed as volume fraction per cortex. Tubules from control animals contained no visible glycogen, as opposed to a content of about 1% in both diabetic groups. We concluded that an aldose reductase inhibitor does not aggravate this tubular lesion (i.e., the Armanni-Ebstein lesion) in rats with experimental diabetes.

Aldehyde Reductase↗